Naviter Wealth LLC Reduces Stake in Danaher Corporation $DHR

Naviter Wealth LLC reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 5.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,682 shares of the conglomerate’s stock after selling 481 shares during the period. Naviter Wealth LLC’s holdings in Danaher were worth $1,718,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. MGO One Seven LLC grew its holdings in Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares during the period. Chicago Capital LLC grew its stake in shares of Danaher by 11.6% during the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after acquiring an additional 1,391 shares during the period. UniSuper Management Pty Ltd increased its holdings in Danaher by 1.6% in the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after acquiring an additional 2,667 shares during the last quarter. Asahi Life Asset Management CO. LTD. bought a new stake in Danaher in the 1st quarter valued at about $539,000. Finally, Horizon Financial Services LLC lifted its holdings in Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock valued at $1,681,000 after purchasing an additional 8,160 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 11.20% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $205.36 on Tuesday. The stock’s 50-day simple moving average is $200.82 and its two-hundred day simple moving average is $197.06. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.41. The firm has a market capitalization of $147.05 billion, a P/E ratio of 43.69, a P/E/G ratio of 2.88 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is presently 27.23%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DHR shares. Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Barclays reiterated an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Robert W. Baird increased their target price on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. Guggenheim reiterated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective on the stock in a report on Friday, July 11th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $244.60.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.